This program will inform clinicians of immunopathological assessment of melanoma especially in relation to patterns of resistance, the advantages of novel combination immunotherapies in the treatment of melanoma, and the evaluation of associated toxicities and their management in patients.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024

This educational virtual pathways program will help healthcare providers to optimize immunopathological assessment of melanoma, particularly in consideration of patterns of resistance. Specifically, the programming will improve clinicians’ knowledge of the latest data on combination therapies in advanced melanoma across settings of care, while preparing them to manage adverse events with these combination therapies for advanced melanoma.

RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024

This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.

RELEASED DATE: January 24, 2024
EXPIRATION DATE: January 24, 2025

Through this virtual preceptorship program, learners will evaluate current and emerging applications of bispecific antibodies in the management of non-Hodgkin lymphoma, as informed by the latest data. With multiple novel bispecific antibodies targeting CD20 on malignant B cells and CD3 on immune effector T cells, there is an increasing need for awareness of the efficacy, safety, and best practices for use of these therapies in relapsed and refractory forms of non-Hodgkin lymphomas. In addition to recognizing clinical data and mechanisms, this program discusses potential adverse events associated with bispecific antibody therapies and best practices for their monitoring and management. This unique program enables clinicians to understand the design, mechanisms, and safety and efficacy data informing the integration of bispecific antibodies in management of non-Hodgkin lymphomas.

RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025

This enduring educational activity will provide important information on the burden of Paroxysmal Nocturnal Hemoglobinuria (PNH) on patient quality of life, the pathophysiology of PNH, and the latest efficacy and safety data on existing and emerging therapeutic options.

RELEASED DATE: October 19, 2023
EXPIRATION DATE: October 26, 2024

Monday, June 3, 2024

6:30 pm – 7:30 pm CT

Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific

Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025

This enduring is designed to assist veterans’ affairs-associated members of the multi-disciplinary oncology care team in evaluating current developments in the use of novel bispecific antibody therapies in later-line management of Non-Hodgkin’s Lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and current efficacy and safety data associated with adverse event management in NHL.

RELEASED DATE: January 18, 2024
EXPIRATION DATE: January 18, 2025

This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in cutaneous squamous cell carcinoma.

RELEASED DATE: August 10, 2023
EXPIRATION DATE: August 10, 2024

This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about biomarkers that guide treatment selection, novel immunotherapy treatment strategies, and the critical role of multidisciplinary management to individualize care in non-small cell lung cancer.

RELEASED DATE: September 28, 2023
EXPIRATION DATE: September 28, 2024